Lymphadenopathy News and Research

RSS

Lymphadenopathy refers to the enlargement of one or more lymph nodes, the bean-shaped glands found in the neck, armpits, chest, groin, and abdomen. Lymphadenopathy may occur in just one part of the body, in which case it is referred to as “localized” or it may be present in two or more body areas, in which case it is referred to as “generalized.” The condition most commonly affects nodes in the neck (cervical lymph nodes).

Previous SARS-CoV-2 infection associated with more adverse events following mRNA vaccination

The phase 3 trials of the Pfizer and Moderna COVID-19 vaccines did not include those with a known previous SARS-CoV-2 infection. Recent evidence indicates that mRNA vaccines may induce more adverse events in these individuals. In a recent study, 947 individuals, 265 of which have previously reported SARS-CoV-2 infection, were monitored post-vaccination for adverse events, finding that there could be a link between previous infection and greater incidence of these events.

26 Apr 2021

New study explores post-COVID-19 inflammatory condition in children

In recent weeks, a multisystem hyperinflammatory condition has emerged in children in association with prior exposure or infection to SARS-CoV-2.

25 Jun 2020

ATS publishes first official clinical practice guidelines for sarcoidosis

New guidance is available for physicians who must go through a number of steps to provide a probable diagnosis of sarcoidosis - an inflammatory disease that affects the lungs, lymph glands, and other organs.

20 Apr 2020

Chest CT shows COVID-19 damage to the lungs

A new study presents peer-reviewed cases of COVID-19 in order to ensure that the disease is diagnosed as rapidly as possible, and thus help prevent an overwhelming spike in infections in any one place during the course of the current pandemic. Much interest has been shown in the possibility of using chest X-rays, and computed tomography (CT) scans to screen for and diagnose patients with this illness, whether suspected or confirmed.

15 Mar 2020

Coronavirus: CT scans of chest could help in early diagnosis

Researchers have managed to radiologically view the novel coronavirus infected individuals, and this could be a step towards early detection of this virus and diagnosis of those infected by it. The study titled, “CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV),” was published this week in the journal Radiology.

5 Feb 2020

Study reveals how a regulatory molecule ensures appropriate supply of blood cells

The body needs to create a continuous supply of blood cells to enter circulation. Blood cells have a wide variety of functions ranging from supplying oxygen to tissues, fighting infections, and enabling the blood to clot upon injury.

13 Mar 2019

Celgene to share new and updated data around novel hematological therapies

Celgene Corporation today announced that data from a broad range of early and late stage studies evaluating Celgene investigational agents and investigational uses of marketed products will be presented at the 23rd European Hematology Association annual meeting in Stockholm, Sweden, from June 14-17, 2018.

22 May 2018

Tattoo ink from 15 years ago mimics lymph node cancer: Case study

A 30 year old Australian woman presented to the doctors with numerous small lumps under her arms for around two weeks. When one of the nodes were put under the microscope, the doctors found pigments from tattoo ink that she’d got 15 years back.

4 Oct 2017

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly.

28 May 2016

Post-treatment imaging can help detect recurrences of HPV-positive oropharyngeal cancer

For patients treated with definitive radiation therapy (RT) for oropharyngeal cancer caused by human papillomavirus (HPV), the majority of recurrences can be detected by post-treatment imaging at three months and physical exams during the six months following treatment, according to research presented at the 2016 Multidisciplinary Head and Neck Cancer Symposium.

19 Feb 2016

Training advised to plug lung cancer care gaps

Guideline-consistent care for patients with suspected lung cancer with mediastinal lymphadenopathy without distant metastases varies by region and physician characteristics, say researchers.

5 Dec 2013

Phase 3 study of idelalisibin reports positive results in CLL patients

Following a recommendation by an independent Data Monitoring Committee (DMC), Gilead Sciences, Inc. (Nasdaq:GILD) today announced that its Phase 3 study (Study 116) evaluating idelalisib in previously-treated chronic lymphocytic leukemia (CLL) patients who are not fit for chemotherapy will be stopped early.

10 Oct 2013

Brake for skin inflammation discovered

The absence of a protein called Ctip2 in the skin allows increased levels of T-helper 2 cytokines and may have a role in conditions such as atopic dermatitis, research in mice suggests.

4 Jan 2013

Article describes immune-related adverse events with newly approved melanoma drug

An internationally recognized melanoma researcher at Moffitt Cancer Center and colleagues at the University of Kiel in Germany, including Axel Hauschild, M.D. and Katharina C. K-hler, M.D., have published an article in the current issue of The Journal of Clinical Oncology that describes immune-related adverse events for patients receiving either tremelimumab or ipilimumab, the latter a drug approved last year by the U.S. Food and Drug Administration for treating metastatic melanoma and other cancers.

23 Aug 2012

Positive results from XIAFLEX phase IIIb multicord trial for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line data from its open-label phase IIIb trial evaluating XIAFLEX for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. The Company enrolled 60 patients at eight sites throughout the U.S. and Australia.

30 Jul 2012

FDA approves XenoPort, GSK’s Horizant ER tablets for management of PHN

GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced today that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended-Release Tablets for the management of postherpetic neuralgia (PHN) in adults.

7 Jun 2012

Gilead commences GS-1101 Phase 3 trial in CLL

Gilead Sciences, Inc. today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.

2 May 2012

Rheumavax safe and feasible in treating RA

A vaccine designed to re-educate the immune system has been shown to be safe and feasible in the treatment of rheumatoid arthritis, according to research presented this week at the American College of Rheumatology Annual Scientific Meeting in Chicago.

7 Nov 2011

Study explains why some people experience repeated infections of Lyme disease

The bacteria that cause Lyme disease, one of the most important emerging diseases in the United States, appear to hide out in the lymph nodes, triggering a significant immune response, but one that is not strong enough to rout the infection, report researchers at the University of California, Davis.

17 Jun 2011

Rwanda, QIAGEN and Merck launch comprehensive national cervical cancer prevention program

The Government of Rwanda, together with QIAGEN N.V. and Merck, known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.

From QIAGEN Manchester Limited 25 Apr 2011